Files in this item

FilesDescriptionFormat

application/pdf

application/pdfKONOPKA-DISSERTATION-2019.pdf (5MB)Restricted Access
(no description provided)PDF

Description

Title:Targeting the receptor for advanced glycation end products with a quantitative multimodal imaging method for precision medicine
Author(s):Konopka, Christian James
Director of Research:Dobrucki, Wawrzyniec L
Doctoral Committee Chair(s):Dobrucki, Wawrzyniec L
Doctoral Committee Member(s):Smith, Andrew M; Pan, Dipanjan; Kajdacsy-Balla, Andre
Department / Program:Bioengineering
Discipline:Bioengineering
Degree Granting Institution:University of Illinois at Urbana-Champaign
Degree:Ph.D.
Genre:Dissertation
Subject(s):Molecular Imaging
Receptor For Advanced Glycation End Products
Prostate Cancer
Nanoparticles
PET-CT
Abstract:The Receptor for Advanced Glycation End Products (RAGE) has been shown to contribute to a myriad of pathologies including nephropathy, Alzheimer’s disease, cardiomyopathy, and pulmonary, ocular, arterial, and atherosclerotic diseases. It has been shown that RAGE expression levels are high during development but markedly decreased in adult tissues; while on the other hand, RAGE expression in adult tissues is significantly augmented by increased levels of ligands named advanced-glycation end-products (AGEs), which are observed in pathological states including inflammation, diabetes, renal and heart failure, and cancer. Yet, the study of RAGE and its ligands in their relation to cancer progression are still in their early stages. Significantly, however, RAGE and its ligands have been shown to be both over expressed and critical to prostate cancer (PCa) development. Importantly, overexpression of RAGE and its ligand HMGB1 clinically has been shown to be associated with poor PCa patient survival, suggesting its promise as a molecular target for imaging and therapeutics. In this work, we developed and employed a nanoparticle-based imaging strategy of RAGE, first in a model of hind-limb ischemia (a widely-studied pathological model for RAGE signaling), and subsequently in PCa. Finally, we demonstrate the utility of this probe and the potential import RAGE and its ligands may play in disease, by using this RAGE-targeted imaging strategy to track the effects of dietary Advanced Glycation End Products on PCa progression. This strategy allows for the development of precision clinical assessment and treatment paradigms, while highlighting the import of this receptor.
Issue Date:2019-12-06
Type:Text
URI:http://hdl.handle.net/2142/106486
Rights Information:Copyright 2019 Christian J. Konopka
Date Available in IDEALS:2020-03-02
Date Deposited:2019-12


This item appears in the following Collection(s)

Item Statistics